vs
EXACT SCIENCES CORP（EXAS）与Primerica, Inc.（PRI）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Primerica, Inc.的1.0倍（$878.4M vs $872.7M），Primerica, Inc.净利率更高（21.8% vs -9.8%，领先31.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.4%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 4.2%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Primerica, Inc.是一家采用多层次营销模式的金融服务机构，业务覆盖美国与加拿大市场，主要面向当地中等收入家庭提供保险、投资等多元化金融产品，满足客户的风险保障与差异化财富管理需求。
EXAS vs PRI — 直观对比
营收规模更大
EXAS
是对方的1.0倍
$872.7M
营收增速更快
EXAS
高出14.7%
8.4%
净利率更高
PRI
高出31.6%
-9.8%
两年增速更快
EXAS
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $872.7M |
| 净利润 | $-86.0M | $190.1M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.8% | 21.8% |
| 营收同比 | 23.1% | 8.4% |
| 净利润同比 | 90.1% | 12.4% |
| 每股收益（稀释后） | $-0.45 | $5.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPRI
| Q1 26 | — | $872.7M | ||
| Q4 25 | $878.4M | $853.7M | ||
| Q3 25 | $850.7M | $839.9M | ||
| Q2 25 | $811.1M | $793.3M | ||
| Q1 25 | $706.8M | $804.8M | ||
| Q4 24 | $713.4M | $768.8M | ||
| Q3 24 | $708.7M | $774.1M | ||
| Q2 24 | $699.3M | $803.4M |
净利润EXASPRI
| Q1 26 | — | $190.1M | ||
| Q4 25 | $-86.0M | $197.0M | ||
| Q3 25 | $-19.6M | $206.8M | ||
| Q2 25 | $-1.2M | $178.3M | ||
| Q1 25 | $-101.2M | $169.1M | ||
| Q4 24 | $-864.6M | $167.1M | ||
| Q3 24 | $-38.2M | $164.4M | ||
| Q2 24 | $-15.8M | $1.2M |
毛利率EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | 98.0% |
营业利润率EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | 28.9% | ||
| Q3 25 | -3.0% | 32.3% | ||
| Q2 25 | -0.3% | 29.6% | ||
| Q1 25 | -13.6% | 27.5% | ||
| Q4 24 | -122.8% | 64.7% | ||
| Q3 24 | -5.6% | 32.9% | ||
| Q2 24 | -3.8% | 1.0% |
净利率EXASPRI
| Q1 26 | — | 21.8% | ||
| Q4 25 | -9.8% | 23.1% | ||
| Q3 25 | -2.3% | 24.6% | ||
| Q2 25 | -0.1% | 22.5% | ||
| Q1 25 | -14.3% | 21.0% | ||
| Q4 24 | -121.2% | 21.7% | ||
| Q3 24 | -5.4% | 21.2% | ||
| Q2 24 | -2.3% | 0.1% |
每股收益（稀释后）EXASPRI
| Q1 26 | — | $5.97 | ||
| Q4 25 | $-0.45 | $6.11 | ||
| Q3 25 | $-0.10 | $6.35 | ||
| Q2 25 | $-0.01 | $5.40 | ||
| Q1 25 | $-0.54 | $5.05 | ||
| Q4 24 | $-4.69 | $4.92 | ||
| Q3 24 | $-0.21 | $4.83 | ||
| Q2 24 | $-0.09 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $645.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.5B |
| 总资产 | $5.9B | $14.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPRI
| Q1 26 | — | $645.8M | ||
| Q4 25 | $964.7M | $756.2M | ||
| Q3 25 | $1.0B | $644.9M | ||
| Q2 25 | $858.4M | $621.2M | ||
| Q1 25 | $786.2M | $625.1M | ||
| Q4 24 | $1.0B | $687.8M | ||
| Q3 24 | $1.0B | $550.1M | ||
| Q2 24 | $946.8M | $627.3M |
股东权益EXASPRI
| Q1 26 | — | $2.5B | ||
| Q4 25 | $2.4B | $2.4B | ||
| Q3 25 | $2.5B | $2.3B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.4B | $2.3B | ||
| Q4 24 | $2.4B | $2.3B | ||
| Q3 24 | $3.2B | $1.9B | ||
| Q2 24 | $3.2B | $2.1B |
总资产EXASPRI
| Q1 26 | — | $14.7B | ||
| Q4 25 | $5.9B | $15.0B | ||
| Q3 25 | $5.9B | $14.8B | ||
| Q2 25 | $5.8B | $14.8B | ||
| Q1 25 | $5.7B | $14.6B | ||
| Q4 24 | $5.9B | $14.6B | ||
| Q3 24 | $6.7B | $14.8B | ||
| Q2 24 | $6.7B | $14.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $338.2M | ||
| Q3 25 | $219.9M | $202.9M | ||
| Q2 25 | $89.0M | $162.6M | ||
| Q1 25 | $30.8M | $197.5M | ||
| Q4 24 | $47.1M | $270.6M | ||
| Q3 24 | $138.7M | $207.3M | ||
| Q2 24 | $107.1M | $173.3M |
自由现金流EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — |
自由现金流率EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — |
资本支出强度EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — |
现金转化率EXASPRI
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 1.62× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 147.98× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PRI
暂无分部数据
